Review article

Understanding thrombophilia: a review of laboratory testing and clinical implications.

RUNNING TITLE: Understanding thrombophilia

1. **Dr.Abhishek H N**, Assistant professor, Department of Anaesthesiology, Vydehi Institute Of Medical Sciences, Bangalore-560066.
Mobile number:
abhishekhn78@gmail.com,
Orcid- 0000-0001-9035-8898.
2. **Dr Shrey Goel**, Consultant Anesthetiologist, Department of Anesthesia, Neelam hospital, Rajpura, Punjab,
Mobile number: 8054383904
shrey12goel@gmail.com.
3. Dr. Preeti Prakash Kale
Lecturer at Department of Periodontology ,Pravara Rural Dental College and Hospital, Loni. 413736, Dist: Ahmednagar, State : Maharashtra, India.
Mobile number: 8956445655
Email id: preetikale20jan@gmail.com
ORCID ID: 0000-0003-3753-4105
4. Dr. Ameet Mani
Professor and Head at Department of Periodontology, Pravara Rural Dental College and Hospital, Loni
Email id: ameetmani2007@rediffmail.com
5. Hussam Daghistani
Assistant Professor at department of clinical biochemistry, Faculty of medicine
King Abdulaziz University , Jeddah,Saudi Arabia
Orcid id: 0000-0001-8491-8350
Email id: hmdaghistani@kau.edu.sa
Mobile number: 00966556671718

CORRESPONDENCE ADDRESS:

Dr. Preeti Prakash Kale
Lecturer at Department of Periodontology ,Pravara Rural Dental College and Hospital, Loni. 413736, Dist: Ahmednagar, State : Maharashtra, India.
Mobile number: 8956445655
Email id: preetikale20jan@gmail.com
ORCID ID: 0000-0003-3753-4105

Abstract:

Thrombophilia is a group of inherited or acquired disorders that increase the risk of blood clotting in veins and arteries. Thrombophilia profile refers to a panel of laboratory tests used to identify these disorders, including activated protein C resistance, antithrombin III, protein C and protein S deficiencies, and elevated homocysteine levels. These tests help to diagnose thrombophilia and determine the appropriate treatment, which may involve anticoagulant medications, lifestyle modifications, or replacement therapy with specific proteins. Thrombophilia profile testing is especially important in individuals with a personal or family history of blood clots, recurrent miscarriages, or unexplained thrombosis. Early identification and treatment of thrombophilia can help to prevent potentially life-threatening complications.

Keywords: Thrombophilia, protein C resistance, profile testing, homocysteine

Introduction: Thrombophilia is a medical condition that refers to an increased tendency to develop blood clots in the veins or arteries. The condition is caused by genetic or acquired factors that disrupt the normal balance of the clotting system in the body. Inherited thrombophilia is caused by genetic mutations that affect the normal functioning of proteins involved in blood clotting, such as factor V Leiden mutation, prothrombin gene mutation, and deficiencies of antithrombin, protein C, or protein S. These genetic mutations increase the risk of developing blood clots, particularly in the deep veins of the legs (deep vein thrombosis or DVT) and in the lungs (pulmonary embolism).[1] Acquired thrombophilia can occur due to certain medical conditions, such as cancer, autoimmune diseases, pregnancy, and surgery. It can also be caused by medications, such as hormonal contraceptives and hormone replacement therapy. Thrombophilia can be diagnosed through blood tests that measure the levels and activity of clotting factors in the blood. Treatment depends on the underlying cause and may include blood-thinning medications, such as anticoagulants, and lifestyle modifications to reduce the risk of blood clots.[2]

Causes of thrombophillia

Thrombophilia can be caused by genetic or acquired factors. Inherited thrombophilia is caused by genetic mutations that affect the normal functioning of proteins involved in blood clotting, such as: [3]

1. Factor V Leiden mutation: This is the most common genetic mutation associated with thrombophilia, and it affects the protein factor V, making it resistant to degradation by activated protein C.
2. Prothrombin gene mutation: This mutation affects the production of prothrombin, a protein involved in blood clotting.
3. Deficiencies of antithrombin, protein C, or protein S: These are proteins that regulate the clotting process and prevent excessive clotting.

Acquired thrombophilia can occur due to certain medical conditions, such as:[4]

1. Cancer: Cancer cells can release substances that activate blood clotting, and some cancer treatments can also increase the risk of blood clots.
2. Autoimmune diseases: These conditions can cause inflammation and damage to blood vessels, increasing the risk of blood clots.
3. Pregnancy and childbirth: Changes in hormones and increased pressure on the blood vessels during pregnancy can increase the risk of blood clots.
4. Surgery: Certain surgeries, especially those that involve the legs or pelvis, can increase the risk of blood clots.
5. Medications: Some medications, such as hormonal contraceptives and hormone replacement therapy, can increase the risk of blood clots.

Other factors that can increase the risk of thrombophilia include obesity, smoking, prolonged immobility, and a family history of blood clots. [5]

Clinical feature of thrombophilia:

Thrombophilia is a condition characterized by an increased tendency to develop blood clots (thrombosis) in the veins or arteries. Some common clinical features of thrombophilia include: [6]

1. Deep vein thrombosis (DVT): DVT is a common complication of thrombophilia. It occurs when a blood clot forms in a deep vein, usually in the leg. DVT can cause pain, swelling, redness, warmth, and tenderness in the affected area.
2. Pulmonary embolism (PE): PE occurs when a blood clot in a deep vein breaks off and travels to the lungs, causing breathing difficulties, chest pain, rapid heartbeat, and in severe cases, can be life-threatening.
3. Recurrent miscarriages: Women with thrombophilia are at an increased risk of recurrent miscarriages, particularly in the second and third trimesters of pregnancy.
4. Thrombosis in unusual sites: Thrombophilia may also lead to the development of blood clots in unusual sites, such as the liver, brain, and mesenteric vessels.
5. Family history: A family history of thrombophilia or blood clotting disorders is often seen in individuals with thrombophilia.
6. Hypercoagulability: Thrombophilia is characterized by hypercoagulability, which means the blood is more prone to clotting than normal.

It's important to note that thrombophilia is often asymptomatic, meaning individuals may not experience any symptoms until a blood clot develops. Therefore, regular screening and preventive measures are recommended for individuals at high risk of developing thrombophilia.[7-9]

Thrombophilia profile

A thrombophilia profile is a set of laboratory tests that help diagnose and evaluate the risk of thrombophilia, a condition that increases the risk of blood clot formation.[10] The tests included in a thrombophilia profile may vary depending on the individual's medical history,

symptoms, and risk factors.[11] However, some common tests that may be included in a thrombophilia profile are:

1. **Activated protein C resistance (APCR)**: This test measures the ability of protein C to inactivate factor V, a protein that promotes blood clotting. Resistance to activated protein C can indicate a genetic mutation that increases the risk of thrombophilia.
2. **Antithrombin III:** This test measures the levels of antithrombin III, a protein that inhibits blood clotting. Low levels of antithrombin III can increase the risk of thrombophilia.
3. **Protein C and Protein S**: These tests measure the levels of protein C and protein S, which are proteins that help control blood clotting. Low levels of protein C and protein S can increase the risk of thrombophilia.
4. **Lupus anticoagulant (LA):** This test measures the presence of antibodies that interfere with blood clotting. The presence of lupus anticoagulant can increase the risk of thrombophilia.
5. **Factor V Leiden mutation**: This test detects a genetic mutation that increases the risk of thrombophilia by making factor V more resistant to inactivation by protein C.
6. **Prothrombin gene mutation**: This test detects a genetic mutation that increases the production of prothrombin, a protein that promotes blood clotting, and increases the risk of thrombophilia.
7. **Homocysteine:** This test measures the levels of homocysteine, an amino acid that, when elevated, can increase the risk of blood clots. The results of a thrombophilia profile can help guide treatment and management of thrombophilia. It's important to note that a normal thrombophilia profile does not rule out the possibility of developing blood clots, and preventive measures may still be necessary for individuals at high risk.

Activated protein C resistance (APCR) in thrombophilia patient

Activated protein C resistance (APCR) is a laboratory test used to detect a genetic mutation that can cause an increased risk of thrombophilia. The most common cause of APCR is the Factor V Leiden mutation, which is present in about 5% of the general population. In individuals with thrombophilia, APCR is often seen as a reduced ability of activated protein C to inactivate factor V, which is a protein that promotes blood clotting.[12] This results in a pro-coagulant state, where blood clots are more likely to form. Individuals with APCR are at an increased risk of developing deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clotting disorders. APCR is often detected through a blood test that measures the clotting time of blood in the presence and absence of activated protein C. If APCR is detected in a patient with thrombophilia, treatment may involve anticoagulant medications such as heparin and warfarin to prevent the formation of blood clots. Lifestyle changes, such as regular exercise, maintaining a healthy weight, and avoiding smoking, may also be recommended to reduce the risk of blood clots. It's important to note that APCR may also be present in individuals without thrombophilia, and a positive APCR test result does not necessarily indicate the presence of thrombophilia. Therefore, other laboratory tests may be needed to confirm a diagnosis of thrombophilia.[13]

Antithrombin III in thrombophilia patient:

Antithrombin III (AT III) is a protein that helps to control blood clotting. It acts as an inhibitor of several clotting factors, including thrombin and factors Xa and IXa. In individuals with thrombophilia, the levels of AT III may be reduced, leading to an increased risk of blood clotting. In a thrombophilia patient, low levels of AT III can be caused by genetic mutations that affect the production or function of the protein, or by other factors such as liver disease, nephrotic syndrome, or use of certain medications. Individuals with low levels of AT III are at an increased risk of developing deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clotting disorders. The diagnosis of low AT III levels is typically confirmed through a blood test that measures the protein's activity or concentration. Treatment for low AT III levels in thrombophilia patients may include anticoagulant medications such as heparin and warfarin to prevent the formation of blood clots. In some cases, replacement therapy with AT III concentrate may be recommended to increase the levels of the protein and reduce the risk of blood clots.[14]

It's important to note that low AT III levels can also be caused by other factors unrelated to thrombophilia, and a diagnosis of thrombophilia should be made based on a combination of clinical features and laboratory tests. Therefore, other laboratory tests may be needed to confirm a diagnosis of thrombophilia.[15]

Protein C and Protein S in thrombophilia patient:

Protein C and Protein S are two proteins that help regulate blood clotting. Protein C is an anticoagulant protein that helps to prevent the formation of blood clots by inactivating clotting factors. Protein S works as a cofactor for protein C, enhancing its anticoagulant activity. In individuals with thrombophilia, the levels of protein C and protein S may be reduced, leading to an increased risk of blood clotting. This can be caused by genetic mutations that affect the production or function of the proteins, or by other factors such as liver disease or vitamin K deficiency. A deficiency of protein C or protein S can increase the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clotting disorders. The diagnosis of protein C or protein S deficiency is typically confirmed through a blood test that measures the activity or concentration of the proteins. Treatment for protein C or protein S deficiency in thrombophilia patients may include anticoagulant medications such as heparin and warfarin to prevent the formation of blood clots. In some cases, replacement therapy with protein C or protein S concentrate may be recommended to increase the levels of the proteins and reduce the risk of blood clots. It's important to note that a deficiency of protein C or protein S can also be caused by other factors unrelated to thrombophilia, and a diagnosis of thrombophilia should be made based on a combination of clinical features and laboratory tests. Therefore, other laboratory tests may be needed to confirm a diagnosis of thrombophilia. [16]

Homocysteine in thrombophilia patient:

Homocysteine is an amino acid that is produced in the body as a byproduct of methionine metabolism. In individuals with thrombophilia, the levels of homocysteine may be elevated,

leading to an increased risk of blood clotting. High levels of homocysteine in the blood can damage the lining of blood vessels, leading to inflammation and increased blood clotting. Elevated homocysteine levels have been associated with an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clotting disorders. The diagnosis of elevated homocysteine levels in thrombophilia patients is typically confirmed through a blood test that measures the concentration of homocysteine in the blood.[17] Treatment for elevated homocysteine levels in thrombophilia patients may involve lifestyle modifications, such as a healthy diet rich in vitamins B6, B12, and folic acid, as well as regular exercise and avoidance of smoking. In some cases, vitamin supplements may be recommended to reduce homocysteine levels. Anticoagulant medications such as heparin and warfarin may also be prescribed to prevent the formation of blood clots. It's important to note that elevated homocysteine levels can also be caused by other factors unrelated to thrombophilia, such as kidney disease, hypothyroidism, and certain medications. Therefore, a diagnosis of thrombophilia should be made based on a combination of clinical features and laboratory tests. Other laboratory tests may be needed to confirm a diagnosis of thrombophilia.[18]

Conclusion:

In conclusion, thrombophilia profile testing plays a critical role in the diagnosis and management of thrombophilia, a group of disorders that increase the risk of blood clotting in veins and arteries. The tests included in the thrombophilia profile help to identify specific genetic and acquired factors that contribute to the risk of thrombosis, including activated protein C resistance, antithrombin III, protein C and protein S deficiencies, and elevated homocysteine levels. By identifying these risk factors, healthcare providers can tailor treatment strategies to each individual, which may include lifestyle modifications, anticoagulant medications, or protein replacement therapy. Timely and accurate diagnosis and treatment of thrombophilia are essential to prevent potentially life-threatening complications such as deep vein thrombosis, pulmonary embolism, or stroke. Therefore, thrombophilia profile testing should be considered in individuals with a personal or family history of blood clots, recurrent miscarriages, or unexplained thrombosis to help identify and manage this complex disorder.

References:

1. Montagnana M, Lippi G, Danese E. An Overview of Thrombophilia and Associated Laboratory Testing. Methods Mol Biol. 2017;1646:113-135.
2. Dickey TL. The hypercoagulable state as a risk factor for venous thromboembolism. Part 1. JAAPA. 2002 Nov;15(11):28-32, 35.
3. Tapon-Bretaudière J. Bilan biologique de la maladie thromboembolique veineuse [Laboratory testing for venous thromboembolism]. Transfus Clin Biol. 2000 Dec;7(6):549-52.
4. Jennings I, Cooper P. Screening for thrombophilia: a laboratory perspective. Br J Biomed Sci. 2003;60(1):39-51.

5. Francis JL. Laboratory investigation of hypercoagulability. Semin Thromb Hemost. 1998;24(2):111-26.
6. Darvall KA, Sam RC, Adam DJ, Silverman SH, Fegan CD, Bradbury AW. Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. J Vasc Surg. 2009 May;49(5):1235-41.
7. Bradbury AW, MacKenzie RK, Burns P, Fegan C. Thrombophilia and chronic venous ulceration. Eur J Vasc Endovasc Surg. 2002 Aug;24(2):97-104.
8. Graham N, Rashiq H, Hunt BJ. Testing for thrombophilia: clinical update. Br J Gen Pract. 2014 Feb;64(619):e120-2.
9. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;**87**(1):106–112.
10. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;**88**(10):3698–3703.
11. Franchini M. Utility of testing for factor V Leiden. Blood Transfus. 2012;**10**(3):257–259.
12. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-61.
13. Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program. 2004:424-38.
14. Schmidt B, Schellong S. Thrombophile Störungen bei venöser Thromboembolie aus klinischer Perspektive [Thrombophilic disorders in venous thromboembolism. The clinical perspective]. Med Klin (Munich). 2003 Mar 15;98(3):133-9.
15. Pascual-Izquierdo C, Piñera Salmerón P, Temboury Ruiz F, Valcárcel Ferreiras D, Jiménez Hernández S, Salinas Argente R, Del Arco Galán C, de la Rubia Comos J. Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES). Emergencias. 2023 Feb;35(1):44-52.
16. Rubio-Haro R, Quesada-Carrascosa M, Hernández-Laforet J, Ferrer Gómez C, De Andrés J. Diagnostic-therapeutic algorithm for thrombotic microangiopathy. A report of two cases. Rev Esp Anestesiol Reanim (Engl Ed). 2022 Mar;69(3):179-182.
17. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005 ;94(5):907-15.
18. Puddu P. Homocysteine and risk for atherothrombotic events. Cardiologia. 1999 Jul;44(7):627-31.